Divis Laboratories Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f3o536dn0xpbi0d7h0geis02.pdf

Key Takeaways


Margin & Cost Environment

Dr. Murali K. Divi: "I expect that these unstable times of higher raw materials or a little bit effect on the margins is going to be temporary and we should be able to go back to where we were in the next 1-2 years."

Growth Engines & Capacity

Dr. Murali K. Divi: "I love all the growth engines, because some of the growth engines give me a lot of stability, some of the growth engines grow like rockets."

Custom Synthesis & Big Pharma Positioning

Dr. Murali K. Divi: "If there is an NCE, if there is a large volume required, a company like Divi's only can do from NCE to launch commercial supply within 6 months and meet the whole world demand. That is what we have established in the world, which nobody has done in the past."

Export Mix & Supply Chain


Nutraceuticals & Carotenoids


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin floorMaintain 40% EBITDA margin including other incomeOngoing; "always"
Margin recoveryReturn to pre-inflation margin levels as raw material and geopolitical conditions normalizeNext 1-2 years
Generic volume rampReal volume from capacity expansions and DMF filings to materialize after customer qualifications completeAfter 2 years, with some income sooner
Contrast media growthBig growth engine contribution from capacity additions and qualificationsComing 2 years
Contrast media contract upsidePossible 2x upside on existing big pharma contrast media contractUnder discussion
Capex (ex-Kakinada)Rs. 500-600 crores for new technology capabilities (photochemistry, flow chemistry, peptides, ADCs)Next 3-4 years
Kakinada capexStart with ~Rs. 1,000 crores, invest as project progressesConditional on land handover by Andhra Pradesh government
Kakinada project sequencingKakinada taken up first; Krishnapatnam only after Kakinada completesNo date; awaiting land
Capacity headroomMove from 17% to ~20% available capacity via two new SEZ buildingsAs buildings complete
Patent expiry opportunityCapture share of ~$20 billion worth of APIs going off-patent; DMFs submitted or under preparation2023-2025 patent cliff window

Key Metrics

MetricQ1 FY23
Consolidated total revenue₹2,343 cr, growth of 17% YoY
Constant currency growth9% YoY
Profit before tax₹851 cr
Profit after tax₹702 cr
EBITDA margin37.6% (40% including other income), management expects to maintain 40%
Exports share90% of total revenue
Exports to regulated markets74% of total revenue
Product mix (Generics vs Custom Synthesis)47% / 53%
Nutraceutical business revenue₹186 cr, up from ₹138 cr in Q1 FY22
ForEx gain₹56 cr
Assets capitalized during the quarter₹87 cr
Capital work-in-progress₹512 cr underway; current capital work-in-progress about ₹500 cr
Cash on books (as of June 30)₹3,431 cr
Receivables (as of June 30)₹2,155 cr
Inventories (as of June 30)₹2,836 cr
Capacity utilization83%, with about 17% available; two new SEZ buildings under construction could add further headroom
Planned capex (without Kakinada)₹500–600 cr for new technologies and debottlenecking
Kakinada initial investment (if project proceeds)~₹1,000 cr
Raw material cost increasesSolvents up 30% to 50%, some even 100%; lithium up 100% to 200%
Energy cost increasesCoal from ₹6/kg to ₹8–8.5/kg; power from ₹6/unit to ₹8+/unit; generator power from ₹30–40/unit to ₹70–80/unit
Iodine price$80/kg, up from $13/kg
Shipping cost (India to US, 40-ft container)$11,000, roughly 3x the cost a year ago
Revenue growth over last 3 yearsFrom ₹5,000 cr to ₹9,000 cr (profit after tax from ₹1,300 cr to ₹2,960 cr)
Profit after tax growth over last 3 yearsFrom ₹1,300 cr to ₹2,960 cr (revenue from ₹5,000 cr to ₹9,000 cr)
Capex over last 3 years₹2,500 cr (invested, with revenue growing from ₹5,000 cr to ₹9,000 cr)
Top products concentration (FY22)60%, up from 49%
Top 5 customers concentration (FY22)54%, up from 34%
Import dependency (FY22)46%, up from 44%
US share of exports (FY22)44%, up from 24%
Europe share of exports (FY22)33%, down from 47%